Showing 15,661 - 15,680 results of 15,701 for search 'treating data', query time: 0.22s Refine Results
  1. 15661
  2. 15662

    The efficacy, safety and clinical feasibility of a percutaneous atrial septal shunt device for pulmonary arterial hypertension: a single-center cohort study by Mingfei Li, Dandan Chen, Jianing Fan, Dan Tian, Lei Zhang, Xiaochun Zhang, Shasha Chen, Yuan Zhang, Wenzhi Pan, Lihua Guan, Daxin Zhou, Junbo Ge

    Published 2025-02-01
    “…The primary endpoints of the study included the rate of major cardiovascular and cerebrovascular adverse events (MACCEs), serious adverse events (SAEs), and serious device-related adverse events (SADEs) within 12 months of shunt implantation. Data analysis was conducted using SAS 9.3. Results A total of 12 patients were enrolled in the study and successfully completed the operation. 10 subjects had completed 12 months’ follow-up after operation, while two subjects had died. …”
    Get full text
    Article
  3. 15663
  4. 15664
  5. 15665

    Inhibitory effect of chlorogenic acid extract from peach blossoms on growth of Monilinia fructicola by WANG Haijing, ZHANG Man, LI Haiping, WU Meilan, LIU Chunsheng, SU Kai, ZHANG Chenguang, MENG Dong, YANG Qing, SUPRUN Ivan Ivanovich, WU Junkai

    Published 2025-06-01
    “…M. fructicola was cultured on potato dextrose agar (PDA) medium, and mycelium plugs (7 mm diameter) were treated with varying concentrations of CGA extracts (0.2, 0.3 or 0.4 mg·mL-1) or chlorogenic acid standard. …”
    Get full text
    Article
  6. 15666
  7. 15667

    Implementing a nurse-enabled, integrated, shared-care model involving specialists and general practitioners in early breast cancer post-treatment follow-up (EMINENT): a single-cent... by Raymond J. Chan, Fiona Crawford-Williams, Chad Yixian Han, Lee Jones, Alexandre Chan, Daniel McKavanagh, Marissa Ryan, Christine Carrington, Rebecca L. Packer, Megan Crichton, Nicolas H. Hart, Emma McKinnell, Melissa Gosper, Juanita Ryan, Bethany Crowe, Ria Joseph, Carolyn Ee, Jane Lee, Steven M. McPhail, Katharine Cuff, Laisa Teleni, Jon Emery

    Published 2025-03-01
    “…Feasibility and effectiveness outcome measures, including health-related quality of life (primary outcome), physical activity and nutrition, patient experience, and financial toxicity were collected at baseline, and at 3-, 6-, and 12-months, with health service utilisation data at 24-months. Bivariate and multivariable, intention-to-treat analyses were conducted. …”
    Get full text
    Article
  8. 15668

    Ruxolitinib as a treatment strategy for SARS-CoV-2 pneumonia: clinical experience in a real-world setting by Roberto Ovilla-Martinez, Xochitl Cota-Rangel, Jose De La Peña-Celaya, Mariana Alejandra Alvarado-Zepeda, Alejandro Jiménez Sastré, Humberto Azuara Forcelledo, Bernardino Ordoñez Rodriguez, Juan Pulido Broca, Aaron Molina Jaimes, Alejandro Muñiz-Carvajal, Maria Magdalena Bahena García, Eduardo Cervera Ceballos, Nidia Paulina Zapata Canto, Jorge Oscar García Mendez, Omar Noel García Jímenez, Jesus Alberto Salas Heredia, Javier Solis Soto, Ruben Alberto Villalobos Mendez, Gregorio Ignacio Ibarra, Cindy Ledesma de la Cruz, Nora Araujo Martinez, Jessi Juárez Lara, Cecilio Omar Ceballos Zuñiga, Felipe Vicente Villaseñor Pérez, Jose Carlos Herrera Garcia, Patricia Nuche Salazar, Alfredo Dominguez Paregrina, Bertha Arizpe Bravo, Gabriela Enciso Figueroa, Teresita Trujillo, Adriana Miguel Álvarez, Diego de Jesús García Gallegos, Alejandro Ortiz Arroyo, Claudia Ivette Solorzano Soto, Hiram Javier Jaramillo Ramírez, Ibis De la Cruz Hernández, Sergio De Gante Martínez, Guadalupe Esmeralda Montesinos Gómez, Silvia Martínez Velasco, Roberto García Graullera, Miguel Angel Vázquez López, Victor Itaí Urbalejo Ceniceros, Yolanda Lugo García, Ana Itamar González Ávila, Jorge Duque Rodriguez, Rodolfo Ruiz Luján, Violeta I. Rodríguez Rivera, Lucio Soberanes Ramírez, Pamela Elena Baez-Islas

    Published 2022-01-01
    “…Methodology: We analysed the data obtained by an observational cohort of patients with SARS-CoV-2 pneumonia treated with ruxolitinib in 22 hospitals of Mexico. …”
    Get full text
    Article
  9. 15669
  10. 15670

    RO5126766 attenuates osteoarthritis by inhibiting osteoclastogenesis and protecting chondrocytes through mediating the ERK pathway by Han Wang, Xiwen Yuan, Jie Han, Zuoxing Wu, Zheru Ma, Fan Shi, Zhengqiong Luo, Zihan Chen, Chenyang Guo, Guixin Yuan, Xuemei He, Zemin Ling, Lin Meng, Rong Shen, Jianming Huang, Ren Xu

    Published 2025-05-01
    “…Background: Osteoarthritis (OA) is a degenerative joint disease that remains challenging to treat due to lack of complete understanding of its pathogenesis. …”
    Get full text
    Article
  11. 15671

    The spiritual needs and care of children and young people with life-threatening or life-shortening conditions, and parents (SPARK): a mixed-method investigation by Bryony Beresford, Natalie Richardson, Suzanne Mukherjee, Rebecca Nye, Jan Aldridge, Karl Atkin, Mark Clayton, Faith Gibson, Julia Hackett, Richard Hain, Mohammed Arshad, Paul Nash, Bob Phillips

    Published 2025-05-01
    “…Design and research participants A mixed-method, multicomponent design was used with the quantitative and qualitative data collected. There were four work packages. Work package 1: survey of chaplaincy services in the National Health Service acute trusts in England (n = 98/136). …”
    Get full text
    Article
  12. 15672

    Pre-existing oncohematological disease in kidney transplant recipients: impact on graft survival, acute rejection, and long-term clinical outcomes by Alberto Mella, Alberto Mella, Roberta Clari, Roberta Clari, Valeria Deiana, Valeria Deiana, Roberta Giraudi, Roberta Giraudi, Gloria Giovinazzo, Gloria Giovinazzo, Ester Gallo, Ester Gallo, Caterina Dolla, Caterina Dolla, Antonio Lavacca, Antonio Lavacca, Ana Maria Manzione, Ana Maria Manzione, Fabrizio Fop, Fabrizio Fop, Anna Allesina, Anna Allesina, Federica Cavallo, Sara Bringhen, Dario Ferrero, Roberto Mina, Corrado Tarella, Corrado Tarella, Benedetto Bruno, Filippo Mariano, Filippo Mariano, Luigi Biancone, Luigi Biancone

    Published 2025-08-01
    “…IntroductionOncohematological disorders are heterogeneous conditions that present significant challenges in management prior to transplantation. Data about rejection risk, disease recurrence, eligibility criteria, and requested remission time before kidney transplant (KT) are still lacking.MethodsAll KTRs between January 1, 2000, and March 31, 2023 (n = 2871) were analyzed. …”
    Get full text
    Article
  13. 15673
  14. 15674

    Luspatercept for the treatment of lower-risk myelodysplastic syndrome with SF3B1 mutation: a real-world single-center research in China by Weiru Liang, Rui Kang, Yufei Zhao, Lingxiao Xing, Baohang Zhang, Yimeng Shi, Yuan Li, Guangxin Peng, Xin Zhao, Xu Liu, Jing Hu, Xiangrong Hu, Kang Zhou, Yang Yang, Youzhen Xiong, Jianping Li, Huihui Fan, Wenrui Yang, Lei Ye, Liping Jing, Li Zhang, Fengkui Zhang

    Published 2025-12-01
    “…Background Luspatercept, approved by the FDA and EMA for patients with transfusion-dependent lower-risk myelodysplastic syndrome (LR-MDS) unresponsive to erythropoiesis-stimulating agents (ESAs), lacks extensive real-world data, particularly in China.Methods We retrospectively analyzed 14 LR-MDS-SF3B1 patients treated with luspatercept for ≥12 weeks.Results Median age was 60 years (range 47-72); 42.9% were male. …”
    Get full text
    Article
  15. 15675
  16. 15676

    Local elections 2000: analyzing the results of the elections by Alvidas Lukošaitis

    Published 2000-04-01
    “…Not a few statistical data is presented in the work. Author postulates that the elections have elucidated the processes ongoing in the party system and the leaders of the political powers. …”
    Get full text
    Article
  17. 15677

    The transcription factor PbeNAC83 positively regulates the Valsa canker resistance in apple and pear by DOU Zhiqi, CAI Minrui, DU Chenglong, HU Huanhuan, ZUO Cunwu

    Published 2025-08-01
    “…[Methods] Based on transcriptome data, we screened PbeNAC83(Chr9.g47397) and performed bioinformatics analysis on it. …”
    Get full text
    Article
  18. 15678
  19. 15679

    Predictors of Recurrence After Curative Surgery for Stage I Colon Cancer: Retrospective Cohort Analysis of the Italian Society of Surgical Oncology Colorectal Cancer Network Collab... by Giulia Turri, MD, Luigi Martinelli, MD, Daniela Rega, MD, Nicolò Tamini, MD, Lucia Paiano, MD, Simona Deidda, MD, QuocRiccardo Bao, MD, Laura Lorenzon, MD, PhD, Raffaele De Luca, MD, Caterina Foppa, MD, PhD, Valentina Mari, MD, Giovanni Taffurelli, MD, Arcangelo Picciariello, MD, PhD, Patrizia Marsanic, MD, Leandro Siragusa, MD, Francesco Bagolini, MD, Riccardo Nascimbeni, MD, Gianluca Rizzo, MD, PhD, Sara Vertaldi, MD, Michele Zuolo, MD, Giorgio Bianchi, MD, Lisa Marie Rorato, MD, Rossella Reddavid, MD, PhD, Gaetano Gallo, MD, PhD, Lorenzo Crepaz, MD, Alberto Di Leo, MD, Mario Trompetto, MD, Enrico Potenza, MD, Mauro Santarelli, MD, Nicola de’Angelis, MD, PhD, Francesco Ciarleglio, MD, Marco Milone, MD, PhD, Claudio Coco, MD, Guido Alberto Tiberio, MD, Gabriele Anania, MD, Giuseppe S. Sica, MD, PhD, Andrea Muratore, MD, Donato Francesco Altomare, MD, Isacco Montroni, MD, PhD, Maurizio De Luca, MD, Antonino Spinelli, MD, PhD, Michele Simone, MD, Roberto Persiani, MD, Gaya Spolverato, MD, Angelo Restivo, MD, Nicolò de Manzini, MD, Marco Braga, MD, Paolo Delrio, MD, Giuseppe Verlato, MD, PhD, Corrado Pedrazzani, MD, Adriana Gioia, Cristina Vacca, Dario Parini, Giovanni Tomasicchio, Marcello Calabrò, Bruno Sensi, Filomena Misuriello, Carlo Alberto Schena, Silvia Picotto

    Published 2024-12-01
    “…Given the low risk of recurrence of stage I CC, some international guidelines do not recommend intensive follow-up after surgery. However, data on the actual incidence, risk factors, and site of recurrences are scarce. …”
    Get full text
    Article
  20. 15680